Home/Resoundant/Kay Pepin, PhD

KP

Kay Pepin, PhD

Chief Operating Officer

Therapeutic Areas

Liver Diseases Fibrosis

Resoundant Pipeline

Drug	Indication	Phase
Liver MRE for Fibrosis Staging	Liver Fibrosis (MASLD, MASH, Hepatitis)	Approved
MRE as a Biomarker in Clinical Trials	MASH (as a surrogate endpoint)	Biomarker Qualification
MRE for Tumor Characterization	Oncology (Brain, Breast, Prostate Tumors)	Pre-clinical/Research

Leadership Team at Resoundant

Richard L. Ehman, MD

Chief Executive Officer

Rashid Fehmi, CPA

Chief Financial Officer

Mike Kalutkiewicz, MA

Vice President of Global Policy and Communications

Jeremiah Heilman, PhD

Vice President of Design and Engineering

View full Resoundant profile